Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy

PURPOSE: While there is still a significant need to identify potential biomarkers that can predict which patients are most likely to respond to immunotherapy treatments, radiomic approaches have shown promising results. The objectives of this study were to evaluate whether a previously validated rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Roger, Lerousseau, Marvin, Briend-Diop, Jade, Routier, Emilie, Roy, Severine, Henry, Théophraste, Ka, Kanta, Jiang, Rui, Temar, Nawal, Carré, Alexandre, Laville, Adrien, Hamaoui, Anthony, Laurent, Pierre-Antoine, Rouyar, Angela, Robert, Charlotte, Robert, Caroline, Deutsch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621183/
https://www.ncbi.nlm.nih.gov/pubmed/36307149
http://dx.doi.org/10.1136/jitc-2022-004867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621183/
https://www.ncbi.nlm.nih.gov/pubmed/36307149
http://dx.doi.org/10.1136/jitc-2022-004867

Ejemplares similares